{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:01:02Z","timestamp":1780552862005,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.diabres.2022.110205","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:15:03Z","timestamp":1670544903000},"page":"110205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression"],"prefix":"10.1016","volume":"195","author":[{"given":"Hikmat","family":"Permana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Audi Yanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timotius","family":"Ivan Hariyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.diabres.2022.110205_b0005","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2022.110205_b0010","unstructured":"World Health Organization. Coronavirus disease (COVID-19): situation report. Accessed October 24, 2022. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---19-october-2022."},{"key":"10.1016\/j.diabres.2022.110205_b0015","doi-asserted-by":"crossref","unstructured":"Hariyanto TI, Putri C, Hananto JE, Arisa J, Fransisca V Situmeang R, Kurniawan A. Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression. J Psychiatr Res. 2021 Oct;142:361-368. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.08.031.","DOI":"10.1016\/j.jpsychires.2021.08.031"},{"key":"10.1016\/j.diabres.2022.110205_b0020","first-page":"100557","article-title":"Coronavirus disease 2019 and cardiovascular system: a narrative review","volume":"29","author":"Kwenandar","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"1","key":"10.1016\/j.diabres.2022.110205_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cmi.2021.09.010","article-title":"Obesity, diabetes, hypertension and severe outcomes among inpatients with coronavirus disease 2019: a nationwide study","volume":"28","author":"Bailly","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diabres.2022.110205_b0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sleep.2021.03.029","article-title":"Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis","volume":"82","author":"Hariyanto","year":"2021","journal-title":"Sleep Med"},{"key":"10.1016\/j.diabres.2022.110205_b0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.parkreldis.2021.04.019","article-title":"Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression","volume":"87","author":"Putri","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"10027","key":"10.1016\/j.diabres.2022.110205_b0040","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4\u00b74 million participants","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2022.110205_b0045","doi-asserted-by":"crossref","first-page":"107843s","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1016\/j.diabres.2022.110205_b0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1753-0407.13085","article-title":"Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes","volume":"12","author":"Rajpal","year":"2020","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2022.110205_b0055","doi-asserted-by":"crossref","unstructured":"I, Pinedo-Torres, M, Flores-Fern\u00e1ndez, M, Yovera-Aldana, M, Gutierrez-Ortiz C, Zegarra-Lizana P, Intimayta-Escalante C, et al. Prevalence of Diabetes Mellitus and Its Associated Unfavorable Outcomes in Patients With Acute Respiratory Syndromes Due to Coronaviruses Infection: A Systematic Review and Meta-Analysis. Clin Med Insights Endocrinol Diabetes. 2020 Oct 19;13:1179551420962495. https:\/\/doi.org\/10.1177\/1179551420962495.","DOI":"10.1177\/1179551420962495"},{"issue":"3","key":"10.1016\/j.diabres.2022.110205_b0060","doi-asserted-by":"crossref","first-page":"e00338","DOI":"10.1002\/edm2.338","article-title":"Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: an umbrella systematic review and meta-analysis","volume":"5","author":"Kastora","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2022.110205_b0065","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2337\/dc21-1318","article-title":"COVID-19, Hyperglycemia, and New-Onset Diabetes","volume":"44","author":"Khunti","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.110205_b0070","article-title":"Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection","volume":"19","author":"Hariyanto","year":"2020","journal-title":"Obes Med"},{"issue":"5","key":"10.1016\/j.diabres.2022.110205_b0075","doi-asserted-by":"crossref","first-page":"e0251916","DOI":"10.1371\/journal.pone.0251916","article-title":"DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis","volume":"16","author":"Yang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.diabres.2022.110205_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109031","article-title":"Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression","volume":"179","author":"Hariyanto","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.diabres.2022.110205_b0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1871530321666210709164925","article-title":"Insulin Therapy and Outcome of Coronavirus Disease 2019 (COVID-19): a systematic review, meta-analysis, and meta-regression","volume":"22","author":"Hariyanto","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.diabres.2022.110205_b0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"15","key":"10.1016\/j.diabres.2022.110205_b0095","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2022.110205_b0100","doi-asserted-by":"crossref","unstructured":"MJ, Page, JE, McKenzie, PM, Bossuyt, I, Boutron, TC, Hoffmann, CD, Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.diabres.2022.110205_b0105","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and treatment of new coronavirus pneumonitis. (trial version 5). http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202002\/3b09b894ac9b4204a79db5b8912d4440.shtml."},{"key":"10.1016\/j.diabres.2022.110205_b0110","doi-asserted-by":"crossref","unstructured":"JAC, Sterne, J, Savovi\u0107, MJ, Page, RG, Elbers, NS, Blencowe, I, Boutron et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"6","key":"10.1016\/j.diabres.2022.110205_b0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank","volume":"10","author":"Margulis","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.diabres.2022.110205_b0120","doi-asserted-by":"crossref","unstructured":"P, Sedgwick, Meta-analyses: what is heterogeneity? BMJ. 2015 Mar 16;350:h1435. https:\/\/doi.org\/10.1136\/bmj.h1435.","DOI":"10.1136\/bmj.h1435"},{"issue":"5","key":"10.1016\/j.diabres.2022.110205_b0125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.pcd.2021.08.001","article-title":"Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus","volume":"15","author":"Elibol","year":"2021","journal-title":"Prim Care Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2022.110205_b0130","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/dom.14329","article-title":"Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2","volume":"23","author":"Israelsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.diabres.2022.110205_b0135","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.2337\/dc21-0065","article-title":"N3C Consortium. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes","volume":"44","author":"Kahkoska","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.110205_b0140","doi-asserted-by":"crossref","unstructured":"K, Khunti, P, Knighton, F, Zaccardi, C, Bakhai, E, Barron, N, Holman et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021 May;9(5):293-303. https:\/\/doi.org\/10.1016\/S2213-8587(21)00050-4.","DOI":"10.1016\/S2213-8587(21)00050-4"},{"key":"10.1016\/j.diabres.2022.110205_b0145","doi-asserted-by":"crossref","unstructured":"K, Khunti, Y, Ruan, J, Davies, Field BCT, Harris S, Kosiborod M, et al; ABCD COVID-19 Diabetes National Audit Investigators. Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19. Diabetes Care. 2022 Sep 8:dc220357. https:\/\/doi.org\/10.2337\/dc22-0357.","DOI":"10.2337\/figshare.20452803.v1"},{"issue":"4","key":"10.1016\/j.diabres.2022.110205_b0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4093\/dmj.2020.0146","article-title":"The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu","volume":"44","author":"Kim","year":"2020","journal-title":"South Korea Diabetes Metab J"},{"issue":"9","key":"10.1016\/j.diabres.2022.110205_b0155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.diabres.2022.110205_b0160","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/dom.14704","article-title":"Association between antidiabetic drug use and the risk of COVID-19 hospitalization in the INSIGHT Clinical Research Network in New York City","volume":"24","author":"Min","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2022.110205_b0165","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2337\/db21-0385","article-title":"Diabetes, Drug Treatment, and Mortality in COVID-19: a multinational retrospective cohort study","volume":"70","author":"Nyland","year":"2021","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2022.110205_b0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.dsx.2020.12.020","article-title":"Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: a retrospective study from an academic center in Belgium","volume":"15","author":"Orioli","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.diabres.2022.110205_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01832-2","article-title":"Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study","volume":"18","author":"P\u00e9rez-Belmonte","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.diabres.2022.110205_b0180","doi-asserted-by":"crossref","unstructured":"JM, Ramos-Rinc\u00f3n, LM, P\u00e9rez-Belmonte, FJ, Carrasco-S\u00e1nchez, S, Jansen-Chaparro, M, De-Sousa-Baena, J, Bueno-Fonseca et al; SEMI-COVID-19 Network. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109. https:\/\/doi.org\/10.1093\/gerona\/glab124.","DOI":"10.1093\/gerona\/glab124"},{"issue":"13","key":"10.1016\/j.diabres.2022.110205_b0185","article-title":"Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: a nationwide retrospective cohort study of 235,248 patients in the Russian Federation","volume":"9","author":"Shestakova","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.diabres.2022.110205_b0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.numecd.2020.09.028","article-title":"Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily","volume":"31","author":"Silverii","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.diabres.2022.110205_b0195","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/dom.14256","article-title":"COVID-19 in diabetes in Austria study group. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission","volume":"23","author":"Sourij","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2022.110205_b0200","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.2337\/dc21-1351","article-title":"Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19","volume":"44","author":"Wander","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2022.110205_b0205","doi-asserted-by":"crossref","first-page":"e002774","DOI":"10.1136\/bmjdrc-2022-002774","article-title":"Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland","volume":"10","author":"Yeh","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.diabres.2022.110205_b0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"10.1016\/j.diabres.2022.110205_b0215","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/sim.1461","article-title":"Adjusting for publication bias in the presence of heterogeneity","volume":"22","author":"Terrin","year":"2003","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.diabres.2022.110205_b0220","doi-asserted-by":"crossref","first-page":"e13339","DOI":"10.1111\/eci.13339","article-title":"SGLT2 inhibition and COVID-19: The road not taken","volume":"50","author":"Das","year":"2020","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.diabres.2022.110205_b0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.dsx.2020.04.024","article-title":"Can dapagliflozin have a protective effect against COVID-19 infection? a hypothesis","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"10.1016\/j.diabres.2022.110205_b0230","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabet.2020.06.003","article-title":"SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2022.110205_b0235","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.11.016","article-title":"High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment","volume":"292","author":"Couselo-Seijas","year":"2020","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.diabres.2022.110205_b0240","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium Glucose Cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2022.110205_b0245","doi-asserted-by":"crossref","unstructured":"L, Yu, X, Zhang, S, Ye, H, Lian, H, Wang, J, Ye Obesity and COVID-19: Mechanistic Insights From Adipose Tissue. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1799-1811. https:\/\/doi.org\/10.1210\/clinem\/dgac137.","DOI":"10.1210\/clinem\/dgac137"},{"issue":"1","key":"10.1016\/j.diabres.2022.110205_b0250","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1186\/s12889-021-11546-6","article-title":"Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"21","author":"Cai","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.diabres.2022.110205_b0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clnesp.2022.01.016","article-title":"Coronavirus disease 2019 (Covid-19) outcomes in patients with sarcopenia: a meta-analysis and meta-regression","volume":"48","author":"Siahaan","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.diabres.2022.110205_b0260","doi-asserted-by":"crossref","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"10.1016\/j.diabres.2022.110205_b0265","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2022.110205_b0270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3126\/ajms.v11i6.29911","article-title":"The use of ACE inhibitor\/ARB in SARS-CoV-2 patients: a comprehensive narrative review","volume":"11","author":"Hariyanto","year":"2020","journal-title":"Asian J Med Sci"},{"issue":"11","key":"10.1016\/j.diabres.2022.110205_b0275","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41581-021-00452-0","article-title":"Pathophysiology of COVID-19-associated acute kidney injury","volume":"17","author":"Legrand","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1016\/j.diabres.2022.110205_b0280","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3390\/jcm9072030","article-title":"Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19","volume":"9","author":"Fernandez-Fernandez","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110205_b0285","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.arcmed.2021.08.002","article-title":"Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis","volume":"53","author":"Han","year":"2022","journal-title":"Arch Med Res"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:25:08Z","timestamp":1759173908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722010191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":57,"alternative-id":["S0168822722010191"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110205","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110205"}}